Loading
Life sciences · Journal article
Cardio-oncology · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Occurrence of Colorectal Cancer (CRC) in patients with pre-existing cardiovascular or thrombotic conditions make oncologic decisions and management strategies significantly challenging. An oral chemotherapy drug widely used for CRC in adjuvant, neoadjuvant, and metastatic settings is Capecitabine, an oral fluoropyrimidine. Despite its well-established safety profile, rare metabolic adverse events, such as severe hypertriglyceridemia (HTG), may occur complicating the patient clinical course. Here, we report the case of a 50-year-old man with a longstanding history of thrombophilia (factor V Leiden mutation) who was diagnosed with stenosing sigmoid colon adenocarcinoma under oral anticoagulant treatment (vitamin K antagonists). He underwent laparoscopic left hemicolectomy followed by adjuvant capecitabine therapy. Shortly after treatment initiation, he developed marked HTG, requiring treatment discontinuation, lipid-lowering therapy, multidisciplinary reassessment, and subsequent dose adjustment. The persistent post thrombotic syndrome required continuous anticoagulation. However, oncologic treatment was completed, metabolic abnormalities were progressively controlled, and no disease recurrence was observed. Capecitabine may cause rare HTG. In high-risk patients, strict metabolic monitoring and cardio-oncologic management ensure both chemotherapy efficacy and safety.